Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc.filedCriticalPfizer Products Inc.
Priority to CU20060191ApriorityCriticalpatent/CU23562A3/en
Publication of CU23562A3publicationCriticalpatent/CU23562A3/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof
(AREA)
Abstract
La presente invenciónestá dirigida a una bioconversión regio- y estereoselectiva de dinitrilos alifáticos seleccionados en los correspondientes ácidos cianocarboxílicos. Más particularmente, la presente invención proporciona métodos para la conversión de 2-isobutil-succinonitrilo en ácido (S)-3-ciano-5-metilhexanoico, el cual es un producto intermedio útil en la síntesis de ácido (S)-3-(aminometil)-5-metilhaxanoico (pregabalina). La pregabalina puede usarse para tratar ciertas enfermedades cerebrales, por ejemplo, en el tratamiento y prevención de trastornos repentinos, dolor, y trastornos psicóticos.The present invention is directed to a regional and stereoselective bioconversion of aliphatic dinitriles selected in the corresponding cyanocarboxylic acids. More particularly, the present invention provides methods for the conversion of 2-isobutyl-succinonitrile into (S) -3-cyano-5-methylhexanoic acid, which is an intermediate product useful in the synthesis of (S) -3- ( aminomethyl) -5-methylhaxanoic (pregabalin). Pregabalin can be used to treat certain brain diseases, for example, in the treatment and prevention of sudden disorders, pain, and psychotic disorders.
CU20060191A2006-09-292006-09-29
ESTEREOSELECTIVE BIOCONVERSION OF ALIFATIC DINITRILS IN CYANOCARBOXYLIC ACIDS
CU23562A3
(en)